Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 4:30 PM ET.

Neumora Therapeutics Stock Down 2.6%

Shares of NMRA stock opened at $3.39 on Monday. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65. The stock has a market cap of $566.44 million, a P/E ratio of -2.31 and a beta of 3.20. The company has a 50 day simple moving average of $2.20 and a two-hundred day simple moving average of $2.08.

Insider Activity

In related news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the sale, the insider owned 7,395,185 shares in the company, valued at approximately $25,957,099.35. This trade represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 23,387 shares of company stock worth $82,647 in the last three months. Company insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NMRA. Siren L.L.C. raised its position in shares of Neumora Therapeutics by 44.3% during the fourth quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after buying an additional 1,930,500 shares during the last quarter. Millennium Management LLC lifted its stake in Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after purchasing an additional 1,608,266 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Neumora Therapeutics by 24.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock valued at $2,588,000 after purchasing an additional 281,926 shares during the last quarter. Ikarian Capital LLC grew its position in shares of Neumora Therapeutics by 10,128.9% during the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after purchasing an additional 1,265,910 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Neumora Therapeutics by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 1,003,746 shares of the company’s stock valued at $1,797,000 after purchasing an additional 34,818 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NMRA has been the subject of several analyst reports. Leerink Partners began coverage on Neumora Therapeutics in a research note on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Stifel Nicolaus raised their price objective on Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Mizuho set a $6.00 price objective on Neumora Therapeutics in a research report on Monday, January 5th. Finally, William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.13.

More Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: William Blair upgraded NMRA from Market Perform to Outperform, a catalyst that helped lift shares and drew investor attention. Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Upgraded by William Blair
• Positive Sentiment: Other broker research has become more bullish in recent months (Needham, RBC, Mizuho), with several firms raising price targets — a supportive backdrop for shares and longer‑term sentiment. MarketBeat: Neumora Therapeutics coverage and analyst notes
• Neutral Sentiment: Institutional ownership is meaningful (~47.7%); a mix of hedge funds/institutions recently took or adjusted positions, which can amplify moves but doesn’t signal a directional near‑term catalyst by itself. MarketBeat: Hedge funds and institutional ownership
• Neutral Sentiment: Company profile: Neumora is a clinical‑stage CNS biotech with an R&D pipeline across small molecules, biologics and gene modalities — typical risk/reward profile for a clinical-stage drug developer. MarketBeat: About Neumora Therapeutics
• Negative Sentiment: Multiple insiders sold shares on Feb. 17 (President Joshua Pinto: 5,967 shares; Paul L. Berns: 9,819; Daljit Singh Aurora: 6,165; Michael Lee Milligan: 1,436) — roughly ~23k shares disclosed — which can create downward pressure and signal near‑term caution to investors. Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) President Sells 5,967 Shares of Stock

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.